ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,071.63
0.02%
US Tech 100
16,927.20
-0.78%
Dow Jones
38,460.92
-0.11%
Brent Oil
87.105
-0.13%
Bitcoin
63,743.51
-0.84%
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. NeuroBo Pharmaceuticals Inc (NRBO) Quote

NeuroBo Pharmaceuticals Inc

NeuroBo Pharmaceuticals Inc (NRBO)

NASDAQ
3.10
0.08
(2.65%)
Closed April 24 4:00PM
Delayed by 15 minutes
3.10
0.00
( 0.00% )
Pre Market: 4:00AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.10
Bid
3.01
Ask
3.49
Volume
-
0.00 Day's Range 0.00
2.8888 52 Week Range 6.7499
Market Cap
15.04M
Previous Close
3.10
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
1,437,243
Shares Outstanding
4,851,565
Dividend Yield
-
PE Ratio
-1.21
Earnings Per Share (EPS)
-2.57
Revenue
-
Net Profit
-12.47M

About NeuroBo Pharmaceuticals Inc

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is ... NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.neurobopharma.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
NeuroBo Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NRBO. The last closing price for NeuroBo Pharmaceuticals was $3.10. Over the last year, NeuroBo Pharmaceuticals shares have traded in a share price range of $ 2.8888 to $ 6.7499.

NeuroBo Pharmaceuticals currently has 4,851,565 shares outstanding. The market capitalization of NeuroBo Pharmaceuticals is $15.04 million. NeuroBo Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.21.

NRBO Latest News

More News

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire CAMBRIDGE, Mass., April 17, 2024 Phase 1 Clinical Trial...

April 17 2024
PR Newswire (US)

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire CAMBRIDGE, Mass., April 1, 2024 Full Data Readout...

April 01 2024
PR Newswire (US)

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update PR Newswire CAMBRIDGE, Mass., March 28, 2024 Received First Site Institutional Review Board (IRB...

March 28 2024
PR Newswire (US)

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH PR Newswire CAMBRIDGE, Mass., March 13...

March 13 2024
PR Newswire (US)

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer PR Newswire CAMBRIDGE, Mass., March 4, 2024 CAMBRIDGE, Mass., March 4, 2024...

March 04 2024
PR Newswire (US)

Form 8-K - Current report

March 04 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 29 2024
Edgar (US Regulatory)

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire CAMBRIDGE, Mass., Feb. 29, 2024 First Patient...

February 29 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.53-14.60055096423.633.632.99296593.17007694CS
4-1.14-26.88679245284.244.392.99273503.5895033CS
12-0.86-21.71717171723.966.74992.9914372435.42668969CS
26-0.356-10.30092592593.4566.74992.97089115.3177943CS
52-2.26-42.16417910455.366.74992.88885001675.0116948CS
156-846.5-99.6351224105849.61576.82.88881070798253.13844092CS
260-2192.9-99.8588342441219672002.8888775830312.96001251CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ILAGIntelligent Living Application Group Inc
$ 0.8302
(53.74%)
2.9M
AIREreAlpha Tech Corporation
$ 1.58
(36.21%)
1.44M
CDTXCidara Therapeutics Inc
$ 16.28
(32.47%)
22.92k
MRINMarin Software Incorporated
$ 2.95
(25.00%)
15
VCNXVaccinex Inc
$ 6.20
(23.88%)
1
BPTSBiophytis SA
$ 5.70
(-41.26%)
1.95k
ZAPPZapp Electric Vehicles Group Ltd
$ 2.67
(-31.71%)
605
FBLGraniteShares ETF Trust GraniteShares
$ 19.84
(-25.89%)
83.64k
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.328
(-22.88%)
700.88k
ADTXAditxt Inc
$ 2.02
(-14.77%)
1
SBFMSunshine Biopharma Inc
$ 0.9898
(6.43%)
3.32M
ILAGIntelligent Living Application Group Inc
$ 0.8302
(53.74%)
2.9M
AIREreAlpha Tech Corporation
$ 1.58
(36.21%)
1.44M
NUWENewellis Inc
$ 0.295
(17.02%)
1.39M
SQQQProShares UltraPro Short QQQ
$ 12.09
(2.37%)
1.26M

NRBO Discussion

View Posts
Monksdream Monksdream 3 weeks ago
NRBO 10Q due 4/8
👍️0
SmellMyFinger SmellMyFinger 2 months ago
Here we go... is this finally recovering?
👍️0
Invest-in-America Invest-in-America 2 months ago
NRBO: Remember the old, "Boy-who-cried-WOLF"??? Whelp, now it's, "The-boy-who-cried-WEIGHT-LOSS"!!! (I.e., sooner or later, NOBODY pays any attention!!!)
👍️0
Invest-in-America Invest-in-America 2 months ago
NRBO: And yet ANOTHER pure EXPLOITATION of the suddenly TRENDING "weight loss" craze across BIG-FAT-&-GREASY America!!! Lose weight??? Are you frickin' KIDDING me???!!! Americans LOVE TO BE FAT!!!
👍️0
Monksdream Monksdream 2 months ago
Way up
Weight loss drug developer
👍️0
SmellMyFinger SmellMyFinger 3 months ago
Nothing but crickets here lately.
👍️0
SmellMyFinger SmellMyFinger 5 months ago
Exhaust Gas Recirculation?
👍️0
db101 db101 6 months ago
EGR… 20%
👍️0
SmellMyFinger SmellMyFinger 7 months ago
Won't another reverse/split be necessary soon for compliance?
👍️0
FROZENFLAME FROZENFLAME 7 months ago
Adding !
👍️0
FROZENFLAME FROZENFLAME 7 months ago
$NRBO$
👍️0
SmellMyFinger SmellMyFinger 9 months ago
PPS be chilling below that $1 minimum.
👍️0
SmellMyFinger SmellMyFinger 10 months ago
Financials seem a bit rough for this company.
👍️0
SmellMyFinger SmellMyFinger 11 months ago
Old support became new resistance.
👍️0
tw0122 tw0122 12 months ago
Too much dilution on news won’t run at this pace.
👍️0
tw0122 tw0122 1 year ago
Support at .72 watch this closely
👍️0
tw0122 tw0122 1 year ago
Nice volume yesterday prepping up for a bigger move up. Above .90 with volume and it blows up
👍️0
SmellMyFinger SmellMyFinger 1 year ago
Stocks rarely respond well to reverse/splits. $NRBO does.
👍️0
tw0122 tw0122 1 year ago
Getting there also A.D.c.t similar setup
👍️0
reena969 reena969 1 year ago
I just saw this on my squeeze indicator /chart... seems to be setting up nice. I use your tool for entry postions. It's nice to have. I have been using it since the OTC days. Someone introduce it to me years,years ago. gave me a $13 range on GFAI today $$$ Pivot 12.43, R1 15.96
Happy Trading
👍️0
tw0122 tw0122 1 year ago
Pivot Point 3rd Level Resistance 0.9317
Pivot Point 2nd Level Resistance 0.8933
1-Month High 0.8550
Pivot Point 1st Resistance Point 0.8467
High 0.8100
Previous Close 0.8000
Last 0.7899
Low 0.7810
Pivot Point 1st Support Point 0.7617
Pivot Point 2nd Support Point 0.7233
Pivot Point 3rd Support Point 0.6767
👍️0
Karlchen Karlchen 1 year ago
opened a position yesterday morning

the GOOD: already +
the BAD: not much spare money - very small position.

(invesz´ted big in nWbo)
👍️0
81vette 81vette 1 year ago
Breaking out of the channel with above Ave buy vol.,mon could be a big boom,have a great weekend everyone
👍️0
81vette 81vette 1 year ago
#7 and climbing fast on scanner,relative buy vol. spiking,must be big followed ppl loaded and sharing,golden goose when vol comes,it has fomo/greed potential,dd is more positive than 90% of the garbage currently in play
👍️0
81vette 81vette 1 year ago
unusually low sell vol today,toxic debt/dilution appears ending,super low risk/high reward looking good
👍️0
SmellMyFinger SmellMyFinger 1 year ago
Yes, it has been doing so since 12/28/22.
👍️0
Arnold25764 Arnold25764 1 year ago
Trading in a tight range.
👍️0
tw0122 tw0122 1 year ago
We almost ready for the short squeeze here$$$
👍️0
PENNY DIPZ PENNY DIPZ 1 year ago
ZALMY IS THE NEW ZACK MORRIS!!! EVEN BETTER!!! THANKS MAN FOR ANOTHER 10%, STILL HOLDING SOME MORE JUST IN CASE!!!
👍️0
Arnold25764 Arnold25764 1 year ago
Hi, what possible news coming?
👍️0
tw0122 tw0122 1 year ago
We ready for news and blast off. Warming up again.
👍️0
tw0122 tw0122 1 year ago
I mean added .65s not .55
👍️0
tw0122 tw0122 1 year ago
Just added some .55 for a flip
Have more cash now then market cap
Date Value
December 22, 2022 18.97M
November 11, 2022 6.504M
November 08, 2022 4.036M

https://ycharts.com/companies/NRBO/shares_outstanding
👍️0
tw0122 tw0122 1 year ago
https://finance.yahoo.com/news/neurobo-announces-closing-32-3-210500773.html?.tsrc=rss&guccounter=1
👍️0
BesaoT35 BesaoT35 1 year ago
We were recently( a few days ago) at around 6 million shares outstanding. Now it is at 18 million shares outstanding. Where did the extra 12 million shares come from suddenly? Thanks
👍️0
SmellMyFinger SmellMyFinger 1 year ago
Not just yet, but perhaps soon.
👍️0
SmellMyFinger SmellMyFinger 1 year ago
Shorts prosper in a bearish market, temporarily.
👍️0
SmellMyFinger SmellMyFinger 1 year ago
Consider the full context. Entire market is bearish.
👍️0
SmellMyFinger SmellMyFinger 1 year ago
$NRBO is on the Reg Sho list. Interesting...
👍️0
BesaoT35 BesaoT35 1 year ago
I wonder whether Goldman Sacks will now buy more NRBO at half the price they paid just a few weeks ago. This stock was $29 just a few months ago. The drop in price seems unreal.
👍️0
PENNY DIPZ PENNY DIPZ 1 year ago
BALLA told me to slap that ask so I do as he says!!!!
👍️0
Invest-in-America Invest-in-America 1 year ago
NRBO: Something's going on here.
👍️0
reena969 reena969 1 year ago
Seem like Shorts taking a risk, lets see if it squeezes on a Friday.
👍️0
gr8investment gr8investment 1 year ago
40M in cash too...no offering for a long time
👍️0
reena969 reena969 1 year ago
2.44 looking nice, over 1 million in volume
👍️0
gr8investment gr8investment 1 year ago
Yes sir
👍️0
DawgTrading DawgTrading 1 year ago
This seems ready... took a starter today.
👍️0
BJ-Trader BJ-Trader 1 year ago
Oh boy this baby is oversold and we shall see $5-$10 really soon. This is a bargain. Goldman Sachs is in, so you know what that means.
👍️0
friendVA friendVA 1 year ago
$NRBO New insider Goldman Sachs 1.2M + Upcoming Catalyst + Short interest 41% + Low Float + Oversold + Completed RS + Completed Offering $3

Outstanding Shares 4,035,696 11/4/2022

Volume 43M 2nd all time high
RSI (14) cross above 30
MACD cross and rising
MFI (14) rising

👍️0
PennyPusher786 PennyPusher786 1 year ago
Lol yezzir, hopefully everybody loaded the boat... might just hit 2s and drop again like a week ago
👍️0

Your Recent History

NASDAQ
NRBO
NeuroBo Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved